Analyst Price Targets — IFRX
| Date | Analyst | Firm | Target | Price @ Post | Source | Headline |
|---|---|---|---|---|---|---|
| May 13, 2026 11:27 am | Strong Buy | Raymond James | $9.00 | $2.54 | TheFly | InflaRx upgraded to Strong Buy from Outperform at Raymond James |
| December 3, 2025 11:10 am | — | Leerink Partners | $2.00 | $0.99 | TheFly | InflaRx downgraded to Market Perform from Outperform at Leerink |
| May 29, 2025 8:50 am | — | Raymond James | $2.00 | $0.85 | TheFly | InflaRx downgraded to Outperform from Strong Buy at Raymond James |
| January 6, 2023 4:32 am | — | H.C. Wainwright | $6.00 | $2.92 | Benzinga | HC Wainwright & Co. Maintains Buy on InflaRx, Lowers Price Target to $6 |
Latest News for IFRX
Jena, Germany, June 30, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX), a biopharmaceutical company pioneering anti-inflammatory therapeutics by targeting the complement system, today announced it is assessing the feasibility of broadening its development and registrational strategy for AAV in Europe. The company has initiated this assessment given the recommendation of the European Medicines Agency's (EMA)…
InflaRx N.V. (IFRX) Discusses Strategic Focus on Izicopan for ANCA-Associated Vasculitis and Renal Diseases Transcript
InflaRx NASDAQ: IFRX outlined plans to prioritize development of izicopan, an oral inhibitor of the C5a receptor (C5aR), in ANCA-associated vasculitis (AAV) and other renal diseases during a company conference call led by CEO and founder Niels Riedemann. Get InflaRx alerts:Sign UpIzicopan positioned as a next-generation C5aR inhibitor Riedemann described izicopan as an oral agent designed to block the C5a receptor,…
Jena, Germany, May 08, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today that it has completed its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share. The aggregate gross proceeds from the offering were $150…
Jena, Germany, May 06, 2026 (GLOBE NEWSWIRE) -- InflaRx N.V. (Nasdaq: IFRX) (the “Company”), a biopharmaceutical company pioneering anti-inflammatory therapeutics targeting the complement system, announced today the pricing of its underwritten offering of 75,000,000 ordinary shares of the Company at an offering price of $2.00 per ordinary share.
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for IFRX.
U.S. House Trading
No House trades found for IFRX.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.